Anti-Osteoprotegerin antibody (ab9986)
Key features and details
- Rabbit polyclonal to Osteoprotegerin
- Suitable for: WB
- Reacts with: Human
- Isotype: unknown
Overview
-
Product name
Anti-Osteoprotegerin antibody
See all Osteoprotegerin primary antibodies -
Description
Rabbit polyclonal to Osteoprotegerin -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment corresponding to Human Osteoprotegerin.
Database link: O00300 -
General notes
This product is no longer batch tested in IHC, for an IHC validated antibody please see ab124820
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary. -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
No preservative, sterile filtered -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
unknown -
Light chain type
unknown -
Research areas
Associated products
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9986 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 46 kDa).
To detect hOPG by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hOPG is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. |
Notes |
---|
WB
Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 46 kDa). To detect hOPG by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hOPG is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. |
Target
-
Function
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. -
Tissue specificity
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. -
Involvement in disease
Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal. -
Sequence similarities
Contains 2 death domains.
Contains 4 TNFR-Cys repeats. -
Post-translational
modificationsN-glycosylated. Contains sialic acid residues.
The N-terminus is blocked. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 4982 Human
- Omim: 602643 Human
- SwissProt: O00300 Human
- Unigene: 81791 Human
-
Alternative names
- MGC29565 antibody
- OCIF antibody
- OPG antibody
see all
Images
-
All lanes : Anti-Osteoprotegerin antibody (ab9986) at 1 µg/ml
Lane 1 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
Lane 2 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 46 kDa
Observed band size: 56 kDa why is the actual band size different from the predicted?
Additional bands at: 32 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 150 seconds
Osteoprotegerin contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
Protocols
Datasheets and documents
-
Datasheet download
References (18)
ab9986 has been referenced in 18 publications.
- Lima IFP et al. RANK, RANKL, and OPG in Dentigerous Cyst, Odontogenic Keratocyst, and Ameloblastoma: A Meta-Analysis. Braz Dent J 32:16-25 (2021). PubMed: 33913997
- Zhang JR et al. TNFRSF11B Suppresses Memory CD4+ T Cell Infiltration in the Colon Cancer Microenvironment: A Multiomics Integrative Analysis. Front Immunol 12:742358 (2021). PubMed: 34938284
- Luo Y et al. Disordered metabolism in mice lacking irisin. Sci Rep 10:17368 (2020). PubMed: 33060792
- Sun Y et al. Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway. Int J Endocrinol 2020:8821077 (2020). PubMed: 33488706
- Li S et al. PKC-d deficiency in B cells displays osteopenia accompanied with upregulation of RANKL expression and osteoclast-osteoblast uncoupling. Cell Death Dis 11:762 (2020). PubMed: 32938907